Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

May 05, 2015 8:47 AM ET

Healthcare Equipment and Supplies

Company Overview of Arch Therapeutics, Inc.

Company Overview

Arch Therapeutics, Inc. operates as a life science medical device company. The company focuses on developing products by utilizing a novel approach to stop bleeding and control leaking during surgery and trauma care. Its lead product candidate includes AC5 Surgical Hemostatic Device, a biocompatible synthetic peptide, which comprises naturally occurring amino acids to achieve hemostasis in minimally invasive and open surgical procedures. The company was founded in 2006 and is headquartered in Wellesley, Massachusetts.

20 William Street

Suite 270

Wellesley, MA 02481

United States

Founded in 2006

5 Employees



Key Executives for Arch Therapeutics, Inc.

Co-Founder, Chief Executive Officer, President and Director
Age: 49
Total Annual Compensation: $390.8K
Chief Financial Officer and Treasurer
Age: 56
Total Annual Compensation: $87.2K
Chief Operating Officer
Age: 64
Total Annual Compensation: $253.3K
Compensation as of Fiscal Year 2014.

Arch Therapeutics, Inc. Key Developments

Arch Therapeutics, Inc. Presents at Red Chip Global Online CEO Conference, Apr-22-2015 03:00 PM

Arch Therapeutics, Inc. Presents at Red Chip Global Online CEO Conference, Apr-22-2015 03:00 PM. Speakers: Terrence W. Norchi, Co-Founder, Chief Executive Officer, President and Director.

Arch Therapeutics Announces Favorable Preclinical Data from an Independent Study of AC5 Surgical Hemostatic Device Versus a Popular Fibrin Sealant

Arch Therapeutics, Inc. announced that an independent third party has obtained favorable data from a preclinical animal study that compared the hemostatic activity of AC5 with a popular and commercially available branded fibrin sealant that is indicated for use in controlling bleeding. In this study, full thickness penetrating wounds were surgically created in rat livers, which are highly vascularized parenchymal organs, and then either AC5TM or the fibrin sealant was applied in order to stop the bleeding. The time to hemostasis (TTH), which is the time required to stop bleeding, was measured. The average TTH after application of AC5 was significantly less than 30 seconds. The average TTH for the fibrin sealant was approximately 50% longer. AC5 was maintained at room temperature without requiring cold storage, whereas the fibrin sealant was maintained frozen during storage, in accordance with its prescribing directions. This is a common constraint of many commercial hemostatic agents that are derived from blood-products. Such products also require a multi-step preparation procedure prior to use. AC5 contains a self-assembling peptide comprising naturally occurring amino acids that are not sourced from humans or animals, whereas the fibrin sealant is made from pooled human plasma (blood product). Fibrin sealants and other products that are sourced from human or animal blood products can contain infectious agents, such as viruses and potentially the Creutzfeldt-Jakob disease (CJD) agent, which potentially can be transferred to a patient. The study group intends to submit the data for publication, at which time additional details would be made publicly available. This animal trial was conducted as part of an ongoing series of studies comparing AC5 with currently marketed hemostatic products that are used in surgical procedures.

Arch Therapeutics, Inc. Announces Positive Safety Results for AC5 Surgical Hemostatic Device in Preclinical Toxicity Studies

Arch Therapeutics, Inc. announced that the company obtained additional favorable preclinical data from two planned standardized medical device safety studies in which AC5 was assessed for toxicity to cells and for contamination from pyrogens (toxins that cause fever) produced by bacterial cells. The tests are major components of the panel of biocompatibility testing that medical devices must typically complet e successfullyprior to use in humans. In the cytotoxicity test, which is an in vitro study that assesses AC5 for toxicity to cells using cell cultures, AC5 tested in clinically relevant amounts was found to be non-toxic to cells (non-cytotoxic). In the pyrogenicity test, which is an in vitro study that assesses AC5 for the presence of pyrogens, AC5 tested in clinically relevant amounts was found to be non-pyrogenic, which is a desirable characteristic. Pyrogens, also known as bacterial endotoxins, are certain toxins made by bacteria. A product that were to contain sufficient amounts of pyrogen or other cell-toxins could trigger immune responses with the potential for tissue damage and significant harm to patients. The tests were conducted under guidelines provided by the International Organization for Standardization (ISO), the United States Pharmacopeia (USP), the American National Standards Institute (ANSI) and the Association for the Advancement of Medical Instrumentation (AAMI).

Similar Private Companies By Industry

Company Name Region
Orthodental International, Inc. United States
Peninsula Optical Lab, Inc. United States
SRS Medical Systems, Inc. United States
Prolab Sales, Inc. United States
Ideal Implant Incorporated United States

Recent Private Companies Transactions

Private Placement
March 11, 2015

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Arch Therapeutics, Inc., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at